Overweight Clinical Trial
Official title:
Effect of Weizmania Coagulans BC99 Intervention on Gut Microbiota and Metabolic Markers in Overweight Adults: Randomized, Double-blind, Placebo-controlled Trial
The main purpose of this study is to verify the effects of Weizmania Coagulans BC99 on the gut microbiota and fat related markers (TG, TC, HDL, LDL) in overweight adult subjects. The subjects participate were randomly grouped and receive intervention with Weizmann clotting bacteria BC99 or placebo. The total duration of the study is 8 weeks. After the intervention, blood, urine, and feces samples of the subjects need to be collected and promptly tested in the laboratory. During the intervention period, each group of subjects was required to take the corresponding product daily and record complications.
The main purpose of this study is to verify the effects of Weizmania Coagulans BC99 on the gut microbiota and fat related markers (TG, TC, HDL, LDL) in overweight adult subjects. The subjects participate in the screening on a voluntary basis, and those who pass the screening will enter the trial. Randomly group and receive intervention with Weizmann clotting bacteria BC99 or placebo. The total duration of the study is 8 weeks, including 1 week before the trial (followed up once), 4 weeks during the trial (followed up once a week), and 8 weeks during the trial (followed up once a week). After the intervention, blood, urine, and feces samples of the subjects need to be collected and promptly tested in the laboratory. During the intervention period, each group of subjects was required to take the corresponding product daily and record complications. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
| Terminated |
NCT03299881 -
Safety and Effectiveness of Transcutaneous Electrical Nerve Stimulation (TENS)-Assisted Weight Loss
|
N/A | |
| Completed |
NCT02805478 -
Fat-Associated Cardiovascular Organ Dysfunction
|
||
| Active, not recruiting |
NCT02558920 -
Meta-analyses of Food Sources of Fructose-Containing Sugars and Obesity
|
||
| Completed |
NCT03759743 -
Evaluate the Efficacy and Safety of LMT1-48 on Reducing Body Fat in Overweight Subject
|
N/A | |
| Completed |
NCT03610958 -
Safety and Performance Evaluation of the Epitomee Device for Enhancing Satiety and Weight Loss.
|
N/A | |
| Completed |
NCT03678766 -
CHARGE: Controlling Hunger and ReGulating Eating
|
N/A | |
| Completed |
NCT04430465 -
Effects of Wholegrains on Children's Health (KORN)
|
N/A | |
| Completed |
NCT04117802 -
Effects of Maple Syrup on Gut Microbiota Diversity and Metabolic Syndrome
|
N/A | |
| Completed |
NCT05376865 -
Effects of Vitamin D Supplementation on Obesity, Inflammatory and Metabolic Markers
|
N/A | |
| Completed |
NCT03625427 -
Effect of Palmitoleic Acid on C-reactive Protein
|
N/A | |
| Active, not recruiting |
NCT03435445 -
Online Platform for Healthy Weight Loss (POEmaS)
|
N/A | |
| Enrolling by invitation |
NCT05576116 -
Combined Bariatric Surgery and Pancreas After Kidney Transplantation for Type II Diabetics
|
N/A | |
| Recruiting |
NCT05249465 -
Spark: Finding the Optimal Tracking Strategy for Weight Loss in a Digital Health Intervention
|
N/A | |
| Active, not recruiting |
NCT06023095 -
A Study of LY3502970 in Chinese Participants With Obesity or Are Overweight With Weight-related Comorbidities
|
Phase 1 | |
| Completed |
NCT03648892 -
Brain Dopamine Function in Human Obesity
|
Early Phase 1 | |
| Not yet recruiting |
NCT05751993 -
Piloting a Reinforcement Learning Tool for Individually Tailoring Just-in-time Adaptive Interventions
|
N/A | |
| Recruiting |
NCT02887950 -
Resistant Starch, Epigallocatechin Gallate and Chlorogenic Acid for Body Weight Loss in Menopause
|
N/A | |
| Completed |
NCT02829229 -
Community-based Obesity Treatment in African American Women After Childbirth
|
N/A | |
| Terminated |
NCT02743598 -
Liraglutide for HIV-associated Neurocognitive Disorder
|
Phase 4 |